Jeanette Cancel, MD
Infectious Disease · Ponce, PRNPI 1740246644
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,338 of the $10,622 with a category attached, or 78.5%. 20 manufacturers reported payments, led by Gilead at 44.1% of the total. Among infectious disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 446 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Viiv Healthcare Company$3K
- Theratechnologies Inc.$751
- Merck$740
- Johnson & Johnson$492
- Napo Pharmaceuticals Inc$160
- plus $596 from 14 others
What the payments were for
- Consulting fees$2,09020%
- Food & beverage$8,33879%
- Education$1932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 154 | $4,687 |
| Viiv Healthcare Company | 163 | $3,196 |
| Theratechnologies Inc. | 34 | $751 |
| Merck | 35 | $740 |
| Johnson & Johnson(2 entities) | 29 | $492 |
| Napo Pharmaceuticals Inc | 8 | $160 |
| Janssen Products, LP | 1 | $100 |
| AbbVie | 4 | $84 |
| Exact Sciences | 3 | $62 |
| Hologic Sales And Service, LLC | 2 | $53 |
| SK Life Science, Inc. | 1 | $50 |
| Janssen Scientific Affairs, LLC | 2 | $42 |
| Novo Nordisk | 2 | $41 |
| Aimmune Therapeutics, Inc. | 1 | $32 |
| EMD Serono, Inc. | 2 | $32 |
| Lilly USA, LLC | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| GSK | 1 | $19 |
| VBI Vaccine (delaware) Inc. | 1 | $17 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,622 in reported general payments places this provider in the 90th percentile of 127 infectious disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 820 | $3,212,509 |
| JulucaDolutegravir/Rilpivirine | 262 | $908,603 |
| TivicayDolutegravir Sodium | 182 | $430,087 |
| DescovyEmtricitabine/Tenofov Alafenam | 167 | $352,424 |
| DovatoDolutegravir Sodium/Lamivudine | 112 | $317,709 |
| SunlencaLenacapavir Sodium | 15 | $257,075 |
| PrezcobixDarunavir/Cobicistat | 106 | $252,723 |
| RukobiaFostemsavir Tromethamine | 23 | $193,376 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 42 | $188,638 |
| SerostimSomatropin | 12 | $176,751 |
| CabenuvaCabotegravir/Rilpivirine | 27 | $164,145 |
| Egrifta SvTesamorelin Acetate | 21 | $154,264 |
| OzempicSemaglutide | 72 | $69,387 |
| IsentressRaltegravir Potassium | 25 | $52,860 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 15 | $51,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Sunlenca | $4,687 | $3,822,0081,002 claims |
| Viiv Healthcare CompanyJuluca, Tivicay, Dovato, Rukobia, Cabenuva | $3,196 | $2,013,921606 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $492 | $266,899132 claims |
| Janssen Products, LPSymtuza | $100 | $188,63842 claims |
| EMD Serono, Inc.Serostim | $32 | $176,75112 claims |
| Theratechnologies Inc.Egrifta Sv | $751 | $154,26421 claims |
| MerckIsentress, Pifeltro, Isentress Hd, Januvia | $740 | $116,35077 claims |
| Novo NordiskOzempic | $41 | $69,38772 claims |
| Lilly USA, LLCTrulicity | $25 | $38,84237 claims |
| GSKTrelegy Ellipta | $19 | $20,85335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 127 infectious disease providers in Puerto Rico.
Other infectious disease in Ponce
- Gladys SepulvedaPonce$7K
- Luis Lugo VelezPonce$3K
- Marisel Bosques RosadoHato Rey$247K
- Jorge Santana BagurManati$180K
- Francisco AlvaradoCaguas$69K
- Jorge Bertran-PasarellHato Rey$64K
- Joel Munoz CoreanoBayamon$59K
- Vanessa Olivo EchavarrySan Juan$41K
- Carlos Guzman OrtizAibonito$38K
- Angeles Rodriguez RosaSan Juan$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.